Evidence map›Paper›PMID 25608718›Full record

ArticleGene therapy2015

A scalable method to concentrate lentiviral vectors pseudotyped with measles virus glycoproteins.

M P Marino, M Panigaj, W Ou, J Manirarora, C-H Wei, J Reiser

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Tagging and Capturing of Lentiviral Vectors Using Short RNAs.International journal of molecular sciences · 2021
    Article
  7. Article
  8. Molecular therapy. Methods & clinical development · 2021
    Article
  9. Review
  10. Development of Large-Scale Downstream Processing for Lentiviral Vectors.Molecular therapy. Methods & clinical development · 2020
    Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

M P MarinoDivision of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA.
M PanigajDivision of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA.
W OuDivision of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA.
J ManiraroraDivision of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA.
C-H WeiDivision of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA.
J ReiserDivision of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA.
Center for Biologics Evaluation and Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lentiviral (LV) vectors have emerged as powerful tools for basic research and clinical applications because of their ability to stably transduce both dividing and nondividing cells. A wide range of viral envelope (Env) glycoproteins have the ability to associate with the membrane of LV vectors, a process that is referred to as pseudotyping. Pseudotyped vectors have the capacity to transduce specific cell types for specific applications. For example, LV vectors pseudotyped with the measles virus (MV)-derived hemagglutinin (H) and fusion (F) proteins have the ability to transduce quiescent lymphocytes. In addition, the MV H glycoprotein can be engineered allowing cell-specific targeting of LV vectors. One problem with MV glycoprotein-pseudotyped LV vectors is low titer during vector production. This results in the need to manufacture large volumes of the vectors and to concentrate them to appropriate titers. The commonly used centrifugation-based concentration techniques for LV vectors are not practical for large-scale vector manufacturing. Thus, there is a need for improved methods to concentrate LV vectors. In this study, we adapted an anion-exchange membrane chromatography method that we previously used in the context of LV vectors pseudotyped with the vesicular stomatitis virus glycoprotein to concentate MV glycoprotein-pseudotyped LV vectors. Up to 60% of the input vectors with an up to 5300-fold reduction in volume was achieved using this anion-exchange chromatography method in conjunction with a desalting/concentration step involving centrifugal filter units. This technique provides a rapid and scalable approach for concentrating MV-pseudotyped LV vectors that does not require an elaborate setup.

Indexed as

Cell LineChromatography, Ion ExchangeGenetic VectorsGlycoproteinsHumansLentivirusMeasles virusGlycoproteins

Identifiers

PMID25608718
OpenAlexW1982177726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.